Register Here

Lead Sponsor

Imaging Endpoints

Executive Sponsors

Adaptive Biotechnologies

Associate Sponsors

Cello Health
Fate Therapeutics
Syneos Health
Worldwide Clinical Trials

Supporting Sponsors

Axiom Healthcare Services


Rules-Based Medicine

Educational Partners

Alliance for Regenerative Medicine
Center for Biotechnology
Journal of Immunotherapy and Precision Oncology (JIPO)

Supporting Partner


Media Partners

Big 4 Bio


IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

The 8th Annual Immuno-Oncology 360° Delivers Three Key Benefits:

  1. Access to KOLs driving the science
  2. Partnership opportunities with all stakeholders in Immuno-Oncology
  3. Presentations on the latest data impacting the science, clinical and business advancements in Immuno-Oncology

Additional 2022 Keynotes

2022 Strategic Advisors


2022 Key Topic Areas


  • Discovery/Preclinical Science
  • Cell & Gene Therapy
  • Translational Science
  • Bispecifics
  • Clinical Developments
  • Neoadjuvant/Adjuvant Data
  • Emerging Biomarkers
  • Cytokines
  • Clinical Operations
  • IO Combinations
  • Imaging Advancements
  • Business Developments



Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
  • Partner to expand technology platforms to develop therapeutics at an accelerated rate
  • Receive the latest pre-clinical, translational and clinical data from academia and industry
  • Create and prioritize strategies targeted toward specific tumor types
  • Identify and gain a greater understanding of what assets are available for potential combinations
  • Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
  • Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
  • Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies



Join the conversation early and become part of the IO360° community by following us on LinkedIn and by following the conference hashtag #IO360nyc. If you are interested in participating in the 8th Annual Immuno-Oncology 360° 2022 program, please contact us at Thank you.



Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Strategic Partnerships


Elizabeth Bard
Senior Strategic Partnership Manager

Bre Bugbee
Senior Marketing Manager

Adam Kolanko
Strategic Partnership Manager


Meg Gould
Senior Conference Planner

Danny McCarthy
IO360° Writer/Editor


  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, MD, PhD, Merck

  • "I really enjoyed it and connecting with some really interesting and inspiring people with whom I'm sure this is just the beginning of long standing interactions."

    - Jacqueline Karmel, Roche

  • "Thank you again for the amazing invitation, it was truly my pleasure to be able to participate in the excellent event you organized."

    - Christine Ward, BMS

  • "IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"

    - Jim Mansfield, PerkinElmer

  • "Congratulations again on the excellent program for the Immuno-Oncology 360° meeting. It was truly well coordinated and the topics were fantastic!"

    - Gilson Baia, PhD, Champions Oncology

  • "Really good, well-rounded and novel content. Congratulations on filling the house beyond capacity and for securing such an impressive speaking faculty."

    - Eileen Daniels, Nektar Therapeutics

  • "Thank you for a great conference!"

    - Elena Spanjaard, Pfizer

  • "Your team did a wonderful job in putting together an interesting and relevant program."

    - Lew Bender, Intensity Therapeutics

  • "It was a great conference and I was happy to be a part of it."

    - Anna Pavlick, DO, MD, NYU Cancer Center